Healthequity (NASDAQ:HQY) announced its earnings results on Tuesday. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04, Briefing.com reports. The business had revenue of $56.80 million during the quarter, compared to analysts’ expectations of $55.27 million. Healthequity had a net margin of 20.27% and a return on equity of 13.93%. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS.

Shares of Healthequity (HQY) traded down $0.37 during trading hours on Tuesday, reaching $48.49. 516,436 shares of the company’s stock were exchanged, compared to its average volume of 522,736. Healthequity has a 12-month low of $37.62 and a 12-month high of $55.31. The company has a market cap of $2,950.00, a price-to-earnings ratio of 81.68, a P/E/G ratio of 2.26 and a beta of 1.74.

In other Healthequity news, Director Frank Medici sold 700 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $51.05, for a total transaction of $35,735.00. Following the sale, the director now owns 6,381 shares of the company’s stock, valued at approximately $325,750.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Berkley Capital, Llc sold 373,500 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $53.21, for a total transaction of $19,873,935.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,743,212 shares of company stock worth $91,090,651. Insiders own 19.00% of the company’s stock.

A number of brokerages recently issued reports on HQY. Cantor Fitzgerald reiterated a “buy” rating and set a $56.00 target price on shares of Healthequity in a research report on Tuesday, September 5th. BidaskClub cut shares of Healthequity from a “sell” rating to a “strong sell” rating in a research report on Friday, August 25th. Zacks Investment Research upgraded shares of Healthequity from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Wednesday, November 8th. Oppenheimer reiterated a “buy” rating and set a $61.00 target price on shares of Healthequity in a research report on Wednesday, September 6th. Finally, Robert W. Baird reiterated a “hold” rating on shares of Healthequity in a research report on Thursday, September 21st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Healthequity presently has an average rating of “Buy” and a consensus price target of $57.50.

COPYRIGHT VIOLATION NOTICE: “Healthequity (HQY) Posts Earnings Results, Beats Expectations By $0.04 EPS” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/05/healthequity-hqy-posts-earnings-results-beats-expectations-by-0-04-eps.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Earnings History for Healthequity (NASDAQ:HQY)

Receive News & Stock Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related stocks with our FREE daily email newsletter.